An enzyme that plays a role in activating recently discovered immune cells—Type 1 regulatory cells—during an immune system response may offer a way to use those cells to fight allergies or infection, new research suggests.
“The more we understand about how these cells develop … the more likely we’ll be able to devise approaches to manipulate them.”
Type 1 regulatory (Tr1) cells are a type of regulatory immune cell that help suppress immune responses, including inflammation and tissue damage, but very few details were known about their development and function.
The new study, performed with mice and humans, describes how an enzyme called ITK plays a crucial role in the development of the Tr1 cells during an immune response. The enzyme offers an entry point for researchers to manipulate the development of Tr1 cells to enhance them to treat allergies, for instance, or block their development to treat viral and bacterial infections.
“The more we understand about how these cells develop, the signals and pathways they use, the more likely we’ll be able to devise approaches to manipulate them,” says Avery August, professor of microbiology and immunology in Cornell University’s College of Veterinary Medicine and the paper’s senior author.
Doctors employ antigen immunotherapy to treat allergies by administering a regimen that exposes a patient to increasing doses of an allergen over a period of months. Since allergies are caused by an overactive immune response to an allergen, the treatment works because Tr1 cells help suppress the immune system and lower inflammation. In the future, clinicians may want to enhance the pathway to produce more Tr1 cells, August says.
But when treating viral infections such as the flu, bacterial infections, and tumors, clinicians may want to selectively block the pathway to lower the number of Tr1 cells.
In experiments with mice, August and colleagues found that Tr1 cells increase when a mouse is infected with viruses or bacteria or when fighting tumors. By tempering the development of Tr1 cells, and carefully reducing their activity to suppress the immune response, patients may recover faster from certain diseases.
“This is a balance because these cells are there for a purpose, and we think their purpose is to make sure the immune system doesn’t destroy and cause pathology in an immune response,” August says.
The danger with flu, for example, is that at a certain point other types of immune system T cells, whose purpose is to kill infected cells, start to destroy tissue. In such cases, an overactive immune response can lead to death.
“We’d have to do experiments to find out whether we can tune the function of Tr1 cells,” August says, “so we balance the beneficial aspects of the immune response with the damaging aspects of the immune response.”
In the study, August and his colleagues bred genetically altered mice so they carried a gene that makes Tr1 cells glow green when they develop, which allows for easy tracking. They then bred another type of mouse that had fluorescent Tr1 cells and also allowed the researchers to specifically block the enzymatic activity of ITK. Using the same protocol, they created a third type of mouse that lacked ITK.
In both the mice where ITK was inhibited and the mice that lacked ITK, Tr1 cells failed to develop. Using blood cells from anonymous human volunteers, they got the same results.
In a second experiment, the researchers identified a second critical enzyme in the pathway that leads to the development of Tr1 cells. This other enzyme, called IRF4, is a transcription factor that regulates the expression of a number of genes and proved key for controlling whether Tr1 cells developed. The team also confirmed that the same pathway exists in people.
The study appears in the journal Nature Communications. The National Institutes of Health, the American Association of Immunologists, and the Talent Program of the Third Affiliation Hospital of Sun Yat-sen University in China funded the study.
Source: Cornell University